EMBO JOURNAL-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2021-12-27 衣谷

选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？

77 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2024-05-01 ms2000001028543384 来自陕西省

还没有

6 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2023-11-25 ms2000000406721606

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：细胞生物学
经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开

27 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2021-12-08 slientwo

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：细胞生物学
经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了

118 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2019-11-27 122bcca1m71(暂无昵称)

多久送审呀？liuzx 2018-08-23 发表::
under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表:
under editorial consideration 多久送审？发表过的前辈请明示。

liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。

207 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2019-10-23 喵了个咪5371

想问一下大家，文章状态有变化吗

191 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2019-09-25 medmeds

请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢

178 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2019-06-17 wisper speed

厉害啦iseeyou1210 2017-09-22 发表::
我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表:
我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.

iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.

354 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2018-08-09 ms4185585998171555

请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点

130 0

[GetPortalCommentsPageByObjectIdResponse(id=1089977, encodeId=1dc610899e7a7, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201367, encodeId=3672220136e5d, content=还没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19158209041, createdName=ms2000001028543384, createdTime=Wed May 01 13:28:03 CST 2024, time=2024-05-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2170866, encodeId=c94221e08668e, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：细胞生物学 经验分享：EMBO系列这两天是炸了？为啥投稿界面一直打不开, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5a35505970, createdName=ms2000000406721606, createdTime=Sat Nov 25 09:47:29 CST 2023, time=2023-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078225, encodeId=0c5e10e822593, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：国人接受率不到10%，还是挺好的期刊，能中一篇运气应该挺好的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Dec 08 22:05:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580543, encodeId=0c6e580543d5, content=多久送审呀？liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。liuzx 2018-08-23 02:07:00 发表: under editorial consideration 多久送审？发表过的前辈请明示。, beContent=liuzx 2018-08-23 发表:: under editorial consideration 多久送审？发表过的前辈请明示。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578398, encodeId=c3135e8398f3, content=想问一下大家，文章状态有变化吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/d622df96f8c041cca53c49cabf17ed1d/41be18fc47f84d25bf15563c7d70a5be.jpg, createdBy=97772470812, createdName=喵了个咪5371, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576884, encodeId=e7ff5e6884d6, content=请问大家EMBO J接受后需要上传原始数据吗，要的话需要哪些呢？多谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2115195316, createdName=medmeds, createdTime=Wed Sep 25 08:03:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572343, encodeId=e1e65e2343ff, content=厉害啦iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了.iseeyou1210 2017-09-22 11:45:00 发表: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., beContent=iseeyou1210 2017-09-22 发表:: 我也来贡献一下我的第一次embo投稿经验:第一轮:reviewer1.文章结果很新.解决业界一个大问题.小修即可,review2.文章很好.可以直接接受.他个人有个下建议.随便做做就可以,reviewer3.文章很好.有几个问题没明白.小补实验.拿到reviewer意见.老板说这是他从业20年.遇到过的**的reviewer意见.同时老板也暗自后悔.为毛不送一轮CNS.我们按照审稿意见.做了相关实验.送revision.第二轮:reviewer1.文章非常新.建议editor找个人给我们文章写个特别评论news & views,reviewer3.直接接受.最后.可爱的editor帮我们改了abstract的语言.直接接受了.半个月后.文章的特别评论news & views也发表了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=354, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Mon Jun 17 00:00:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846074, encodeId=de538460e4a2, content=请问两位楼下大神，你们能告诉我具体submittted, under review, revision, accept,的具体时间轴吗，我准备投这个杂志希望两位先辈指点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44e5413969, createdName=ms4185585998171555, createdTime=Thu Aug 09 20:52:29 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553366, encodeId=d5d955336693, content=2018.3.7 实时IF:10.00.今年有所小涨., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df281671460, createdName=iseeyou1210, createdTime=Wed Mar 07 10:17:00 CST 2018, time=2018-03-07, status=1, ipAttribution=)]

2018-03-07 iseeyou1210

2018.3.7 实时IF:10.00.今年有所小涨.

446 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务